Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie’s Disease
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Peyronie's disease (PD) is a debilitating affliction for the male population, causing severe curvatures to the erect penis and erectile dysfunction in about 50% of men. This deviation of the penis significantly impairs sexual intercourse and causes depression and strains in the relationship. As of today, medical treatment options are few and far between, with surgery remaining as the sole reliable treatment. AIM: To give a general overview regarding fibrosis and the specific role of extracellular matrix, macrophages, and myofibroblasts in PD. Additionally, we will provide an overview of past and present research and how this has shaped our vision concerning the pathophysiology of PD. METHODS: We performed a non-systematic literature review using the search terms "fibrosis," "pathophysiology," "myofibroblast," "extracellular matrix," "Peyronie's disease," and "drug discovery." MAIN OUTCOME MEASURE: We assessed current knowledge regarding fibrosis in PD and the possibility to use this knowledge for new treatment options. RESULTS: Interpreting findings from the most recent next-generation sequencing, in vitro and in vivo PD research, we provide novel insights for the pathophysiology of PD. Using this knowledge, we will attempt to provide future directions for PD research and drug discovery, which is urgently needed, because its treatment has essentially been stagnating for about 30 years. CONCLUSION: Historically, PD has not been studied as widely as kidney, lung, or hepatic fibrosis, and our knowledge of its pathophysiology still remains relatively obscure. Nonetheless, recent breakthroughs using stem cells, next-generation sequencing, and phenotypical screening assays bring us several steps closer to filling the gaps in our knowledge. In the near future, clinical trials will prove essential to translate this plethora of preclinical data into usable tools that can improve the lives of many of our patients. Milenkovic U, Ilg MM, Cellek S, et al. Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie's Disease. Sex Med Rev 2019;7:679-689.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Macrophages in Tissue Repair, Regeneration, and Fibrosis
Wynn, T. A., & Vannella, K. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.015 · Cited by 4,481
PERSPECTIVE ARTICLE: Growth factors and cytokines in wound healing
Barrientos, S., Stojadinovic, O., Golinko, M. S., Brem, H., & Tomic‐Canic, M. (2008) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2008.00410.x · Cited by 3,583
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Hinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070112 · Cited by 2,068
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Fibrosis–a common pathway to organ injury and failure
Rockey, D. C., Bell, P. D., & Hill, J. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1300575 · Cited by 1,428
Vascular Remodeling in Hypertension: Roles of Apoptosis, Inflammation, and Fibrosis
Intengan, H. D., & Schiffrin, E. L. (2001) · Hypertension · doi:10.1161/hy09t1.096249 · Cited by 979
Hepatic inflammation and fibrosis: Functional links and key pathways
Seki, E., & Schwabe, R. F. (2015) · Hepatology · doi:10.1002/hep.27332 · Cited by 972
Research works printed but not linked: 79
- Yafi, 2015, Therapeutic advances in the treatment of Peyronie’s disease, Andrology, 3, 650, 10.1111/andr.12058 · DOI
- Gelbard, 1990, The natural history of Peyronie’s disease, J Urol, 144, 1376
- Mulhall, 2006, An analysis of the natural history of Peyronie’s disease, J Urol, 175, 2115
- Kadioglu, 2007, Graft materials in Peyronie’s disease surgery: A comprehensive review, J Sex Med, 4, 581
- Mulhall, 2004, Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening, J Urol, 171, 2350
- Al-Thakafi, 2016, Peyronie’s disease: A literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up, Transl Androl Urol, 5, 280, 10.21037/tau.2016.04.05 · DOI · Paper page
- Hatzichristodoulou, 2017, Contemporary review of grafting techniques for the surgical treatment of Peyronie’s disease, Sex Med, 5, 544
- Russo, 2018, Clinical efficacy of injection and mechanical therapy for Peyronie’s disease: A systematic review of the literature, Eur Urol, 74, 767, 10.1016/j.eururo.2018.07.005 · DOI · Paper page
- El-sakka, 1997, An animal model of Peyronie’s-like condition associated with an increase of transforming growth factor beta mrna and protein expression, J Urol, 158, 2284
- El-Sakka, 1998, Histological and ultrastructural alterations in an animal model of Peyronie’s disease, Br J Urol, 81, 445, 10.1046/j.1464-410x.1998.00529.x · DOI · Paper page
- Vernet, 2002, Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie’s fibrotic plaque and in its rat model, Nitric Oxide Biol Chem, 7, 262, 10.1016/S1089-8603(02)00124-6 · DOI
- Mulhall, 2002, Peyronie’s disease cell culture models: Phenotypic, genotypic and functional analyses, Int J Impot Res, 14, 397, 10.1038/sj.ijir.3900874 · DOI
- Valente, 2003, L-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures, Nitric Oxide, 9, 229, 10.1016/j.niox.2003.12.002 · DOI · Paper page
- Mateus, 2018, Understanding the role of adenosine receptors in the myofibroblast transformation in Peyronie’s disease, J Sex Med, 15, 947
- Ilg, 2019, Antifibrotic synergy between phosphodiesterase type 5 inhibitors and selective oestrogen receptor modulators in Peyronie’s disease models, Eur Urol, 75, 329, 10.1016/j.eururo.2018.10.014 · DOI · Paper page
- Milenkovic, 2019, Simvastatin and the rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Peyronie’s disease–derived fibroblasts via inhibition of YAP/TAZ nuclear translocation, BJU Int, 123, 703, 10.1111/bju.14638 · DOI · Paper page
- Gonzalez-Cadavid, 2004, Molecular pathophysiology and gene therapy of aging-related erectile dysfunction, Exp Gerontol, 39, 1705, 10.1016/j.exger.2004.06.022 · DOI
- Becker, 2001, Pharmacological intervention in renal fibrosis and vascular sclerosis, J Nephrol, 14, 332
- Gholami, 2003, Peyronie’s disease: A review, J Urol, 169, 1234
- Kim, 2016, Exercise-induced rhabdomyolysis mechanisms and prevention: A literature review, J Sport Heal Sci, 5, 324
- Duffield, 2013, Host responses in tissue repair and fibrosis, Annu Rev Pathol Mech Dis, 8, 241, 10.1146/annurev-pathol-020712-163930 · DOI · Paper page
- Lee, 2015, Pathobiology of liver fibrosis: A translational success story, Gut, 64, 830, 10.1136/gutjnl-2014-306842 · DOI · Paper page
- Noble, 2012, Pulmonary fibrosis: patterns and perpetrators, J Clin Invest, 122, 2756, 10.1172/JCI60323 · DOI · Paper page
- Smith, 2016, Update on pulmonary fibrosis: Not all fibrosis is created equally, Arch Pathol Lab Med, 140, 221, 10.5858/arpa.2015-0288-SA · DOI
- Liu, 2011, Cellular and molecular mechanisms of renal fibrosis, Nat Rev Nephrol, 7, 684, 10.1038/nrneph.2011.149 · DOI · Paper page
- Cannito, 2017, Therapeutic pro-fibrogenic signaling pathways in fibroblasts, Adv Drug Deliv Rev, 121, 57, 10.1016/j.addr.2017.05.017 · DOI
- Bollong, 2017, Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis, Proc Natl Acad Sci U S A, 114, 4679, 10.1073/pnas.1702750114 · DOI
- Tian, 2003, An HSV-TK transgenic mouse model to evaluate elimination of fibroblasts for fibrosis therapy, Am J Pathol, 163, 789, 10.1016/S0002-9440(10)63706-6 · doi:10.1016/s0002-9440(10)63706-6
- Hinz, 2015, The extracellular matrix and transforming growth factor-β1: Tale of a strained relationship, Matrix Biol, 47, 54, 10.1016/j.matbio.2015.05.006 · DOI · Paper page
- Milenkovic, 2019, The mechanisms and potential of stem cell therapy for penile fibrosis, Nat Rev Urol, 16, 79, 10.1038/s41585-018-0109-7 · DOI
- Wynn, 2013, Macrophage biology in development, homeostasis and disease, Nature, 496, 445, 10.1038/nature12034 · DOI · Paper page
- McAnulty, 2007, Fibroblasts and myofibroblasts: Their source, function and role in disease, Int J Biochem Cell Biol, 39, 666, 10.1016/j.biocel.2006.11.005 · DOI · Paper page
- Parola, 2008, Myofibroblast-like cells and liver fibrogenesis: Emerging concepts in a rapidly moving scenario, Mol Aspects Med, 29, 58, 10.1016/j.mam.2007.09.002 · DOI · Paper page
- Hinz, 2012, Recent developments in myofibroblast biology, Am J Pathol, 180, 1340, 10.1016/j.ajpath.2012.02.004 · DOI · Paper page
- Novo, 2014, Cellular and molecular mechanisms in liver fibrogenesis, Arch Biochem Biophys, 548, 20, 10.1016/j.abb.2014.02.015 · DOI · Paper page
- Fernández, 2009, Angiogenesis in liver disease, J Hepatol, 50, 604, 10.1016/j.jhep.2008.12.011 · DOI · Paper page
- Gonzalez-Cadavid, 2009, Experimental models of Peyronie’s disease. Implications for new therapies, J Sex Med, 6, 303
- Wynn, 2008, Cellular and molecular mechanisms of fibrosis, J Pathol, 214, 199, 10.1002/path.2277 · DOI · Paper page
- Novo, 2007, Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells, Am J Pathol, 170, 1942, 10.2353/ajpath.2007.060887 · DOI · Paper page
- Udelson, 1998, Engineering analysis of penile hemodynamic and structural-dynamic relationships: Part II—Clinical implications of penile buckling, Int J Impot Res, 10, 25, 10.1038/sj.ijir.3900311 · DOI
- Udelson, 1999, Axial penile buckling forces vs Rigiscan radial rigidity as a function of intracavernosal pressure: Why Rigiscan does not predict functional erections in individual patients, Int J Impot Res, 11, 327, 10.1038/sj.ijir.3900443 · doi:10.1038/sj.ijir.3900443
- Martínez-Salamanca, 2016, α1A-Adrenergic receptor antagonism improves erectile and cavernosal responses in rats with cavernous nerve injury and enhances neurogenic responses in human corpus cavernosum from patients with erectile dysfunction secondary to radical prostatectomy, J Sex Med, 13, 1844
- Zargooshi, 2004, Trauma as the Cause of Peyronie’s Disease: Penile Fracture as a Model of Trauma, J Urol, 172, 186
- Gong, 2003, Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis, J Am Soc Nephrol, 14, 3047, 10.1097/01.ASN.0000098686.72971.DB · DOI · Paper page
- Davila, 2005, Peyronie’s disease associated with increase in plasminogen activator inhibitor in fibrotic plaque, Urology, 65, 645, 10.1016/j.urology.2005.01.010 · DOI
- Massagué, 2000, How cells read TGF-beta signals, Nat Rev Mol Cell Biol, 1, 169, 10.1038/35043051 · DOI · Paper page
- Tsou, 2014, Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription, Am J Physiol Cell Physiol, 307, C2, 10.1152/ajpcell.00060.2014 · DOI
- Ferrini, 2002, Antifibrotic role of inducible nitric oxide synthase, Nitric Oxide, 6, 283, 10.1006/niox.2001.0421 · DOI · Paper page
- Mulhall, 2003, Expanding the paradigm for plaque development in Peyronie’s disease, Int J Impot Res, 15, S93, 10.1038/sj.ijir.3901082 · DOI
- Ferrini, 2004, Aging-related induction of inducible nitric oxide synthase is vasculo-protective to the arterial media, Cardiovasc Res, 61, 796, 10.1016/j.cardiores.2003.12.006 · DOI · Paper page
- Ferrini, 2001, Aging-related expression of inducible nitric oxide synthase and markers of tissue damage in the rat penis, Biol Reprod, 64, 974, 10.1095/biolreprod64.3.974 · DOI · Paper page
- Castiglione, 2013, Intratunical injection of human adipose tissue–derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie’s disease, Eur Urol, 63, 551, 10.1016/j.eururo.2012.09.034 · DOI · Paper page
- Gokce, 2014, Adipose tissue–derived stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie’s disease, Andrology, 2, 244, 10.1111/j.2047-2927.2013.00181.x · DOI · Paper page
- Gokce, 2015, Intratunical injection of genetically modified adipose tissue-derived stem cells with human interferon α-2b for treatment of erectile dysfunction in a rat model of tunica albugineal fibrosis, J Sex Med, 12, 1533
- Jiang, 2017, Inhibition of penile tunica albuginea myofibroblasts activity by adipose-derived stem cells, Exp Ther Med, 14, 5149
- Castiglione, 2019, Intratunical injection of human adipose tissue–derived stem cells restores collagen III/I ratio in a rat model of chronic Peyronie’s disease, Sex Med, 7, 94, 10.1016/j.esxm.2018.09.003 · DOI
- Bias, 1982, Peyronie’s disease: A newly recognized autosomal-dominant trait, Am J Med Genet, 12, 227, 10.1002/ajmg.1320120213 · DOI · Paper page
- Willscher, 1979, The association of histocompatibility antigens of the B7 cross-reacting group with Peyronie’s disease, J Urol, 122, 34
- Leffell, 1982, Non-association of Peyronie’s disease with HLA B7 cross-reactive antigens, J Urol, 127, 1223
- Deguchi, 1984, HLA-A and B antigens in patients with Peyronie disease, Urology, 23, 547, 10.1016/0090-4295(84)90068-2 · DOI
- Hauck, 2003, Prospective analysis of single nucleotide polymorphisms of the transforming growth factor beta-1 gene in Peyronie’s disease, J Urol, 169, 369
- Awad, 1998, Genotypic variation in the transforming growth factor-beta1 gene: Association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation, Transplantation, 66, 1014, 10.1097/00007890-199810270-00009 · DOI · Paper page
- Dolmans, 2011, Wnt signaling and Dupuytren’s disease, N Engl J Med, 365, 307, 10.1056/NEJMoa1101029 · DOI · Paper page
- Magee, 2002, Gene expression profiles in the Peyronie’s disease plaque, Urology, 59, 451, 10.1016/S0090-4295(01)01578-3 · DOI
- Mori, 2000, Modulation of endogenous smad expression in normal skin fibroblasts by transforming growth factor-β, Exp Cell Res, 258, 374, 10.1006/excr.2000.4930 · DOI
- Kavsak, 2000, Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation, Mol Cell, 6, 1365, 10.1016/S1097-2765(00)00134-9 · DOI · Paper page
- Flordellis, 2006, Rethinking target discovery in polygenic diseases, Curr Top Med Chem, 6, 1791, 10.2174/156802606778194226 · DOI
- Nanthakumar, 2015, Dissecting fibrosis: Therapeutic insights from the small-molecule toolbox, Nat Rev Drug Discov, 14, 693, 10.1038/nrd4592 · DOI · Paper page
- Gonzalez-Cadavid, 2010, Treatment of Peyronie’s disease with PDE5 inhibitors: An antifibrotic strategy, Nat Rev Urol, 7, 215, 10.1038/nrurol.2010.24 · DOI
- Dellê, 2012, Antifibrotic effect of tamoxifen in a model of progressive renal disease, J Am Soc Nephrol, 23, 37, 10.1681/ASN.2011010046 · DOI
- Hauck, 2006, A critical analysis of nonsurgical treatment of Peyronie’s disease, Eur Urol, 49, 987, 10.1016/j.eururo.2006.02.059 · DOI
- Tsambarlis, 2018, Surgical management of Peyronie’s disease, Eur Urol Focus, 4, 304, 10.1016/j.euf.2018.08.026 · DOI
- Palmieri, 2012, Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: Results from a prospective randomized trial, Int J Androl, 35, 190, 10.1111/j.1365-2605.2011.01226.x · DOI · Paper page
- Dell’Atti, 2015, Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie’s disease, Urol Ann, 7, 345, 10.4103/0974-7796.152048 · DOI
- Ozturk, 2014, Effects of sildenafil treatment on patients with Peyronie’s disease and erectile dysfunction, Irish J Med Sci, 183, 449, 10.1007/s11845-013-1036-5 · DOI
- Ralph, 1992, The treatment of Peyronie’s disease with Tamoxifen, Br J Urol, 648, 10.1111/j.1464-410X.1992.tb15836.x · DOI · Paper page
- Apaydin, 1998, The use of tamoxifen in the treatment of Peyronie’s disease, Int J Impot Res, 10, S57
- Teloken, 1999, Tamoxifen versus placebo in the treatment of Peyronie’s disease, J Urol, 162, 2003
- Marshall, 2013, Strategies for biomarker discovery in fibrotic disease, Biochim Biophys Acta, 1832, 1079, 10.1016/j.bbadis.2013.01.018 · DOI
Cited by
Comparing and Contrasting Peyronie's Disease Guidelines: Points of Consensus and Deviation.
Manka, M. G., White, L. A., Yafi, F. A., Mulhall, J. P., Levine, L. A., & Ziegelmann, M. J. (2021) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2020.11.013 · Cited by 28
Milenkovic, U., Boeckx, B., Lambrechts, D., Janky, R., Hatzichristodoulou, G., van Renterghem, K., Gevaert, T., Cellek, S., Bivalacqua, T. J., De Ridder, D., et al. (2022) · European Urology Focus · doi:10.1016/j.euf.2021.04.012 · Cited by 14
Self-citationKARAKOSE, A., & YİTGİN, Y. (2024) · Minerva Urology and Nephrology · doi:10.23736/s2724-6051.23.05458-7 · Cited by 11
ABO Blood Type and Risk of Peyronie’s Disease in Japanese Males
Mitsui, Y., Kobayashi, H., Yamabe, F., Nakajima, K., & Nagao, K. (2022) · The World Journal of Men's Health · doi:10.5534/wjmh.210126 · Cited by 7
Yang, C.-H., Lin, D.-Y., Lin, Y.-S., Hsu, C.-Y., Tung, M.-C., Tan, K.-T., & Ou, Y.-C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010777 · Cited by 7
“In mechanism, although there were proposed therapeutic values of regulating macrophages [84,85] and fruitful preclinical studies of applying SC in treating PD, the di‐ rect regulation of macrophages by SC were never demonstrated [14–16,19,20].”
Background
Metadata
- Authors
- Milenkovic, U., Ilg, M. M., Cellek, S., & Albersen, M.
- Venue
- Sexual Medicine Reviews
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-10
- Volume
- 7
- Issue
- 4
- Pages
- 679-689
- ISSN
- 2050-0513 (ISSN-L)
- 2050-0521
- OpenAlex
- W2933207275
- Cited by
- 46
- References
- 28
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie’s Disease. https://app.cochat.ai/papers/10.1016/j.sxmr.2019.02.004
- The paper
- Milenkovic, U., Ilg, M. M., Cellek, S., & Albersen, M. (2019). Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie’s Disease. Sexual Medicine Reviews. https://doi.org/10.1016/j.sxmr.2019.02.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.